The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer

Research output: Contribution to journalArticle

Abstract

Prostate-specific antigen (PSA) is the most important tumor marker for early detection, staging, and monitoring of men with prostatic cancer today. However, its sensitivity and specificity are not sufficient to use it as a single tool for screening for men with clinically localized prostate cancer. Recently, assays have become available that selectively detect several of the various molecular forms of PSA, especially the unbound or free PSA. Several studies have shown the clinical usefulness of percent free PSA (free PSA/total PSA) for the early detection of men with clinically localized prostate cancer. However, the use of percent free PSA for staging of prostate cancer remains controversial. Based on the case scenario presented, the value of total PSA and percent free PSA for the staging of men with clinically localized prostate cancer is reviewed.

Original languageEnglish (US)
Pages (from-to)100-105
Number of pages6
JournalSeminars in Urologic Oncology
Volume16
Issue number3
StatePublished - 1998

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Tumor Biomarkers
Sensitivity and Specificity

Keywords

  • Percent free PSA
  • Prostate cancer
  • PSA
  • Staging

ASJC Scopus subject areas

  • Urology

Cite this

@article{953dde5bb36246dfaa507735afc2cf22,
title = "The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer",
abstract = "Prostate-specific antigen (PSA) is the most important tumor marker for early detection, staging, and monitoring of men with prostatic cancer today. However, its sensitivity and specificity are not sufficient to use it as a single tool for screening for men with clinically localized prostate cancer. Recently, assays have become available that selectively detect several of the various molecular forms of PSA, especially the unbound or free PSA. Several studies have shown the clinical usefulness of percent free PSA (free PSA/total PSA) for the early detection of men with clinically localized prostate cancer. However, the use of percent free PSA for staging of prostate cancer remains controversial. Based on the case scenario presented, the value of total PSA and percent free PSA for the staging of men with clinically localized prostate cancer is reviewed.",
keywords = "Percent free PSA, Prostate cancer, PSA, Staging",
author = "J. Pannek and Partin, {Alan Wayne}",
year = "1998",
language = "English (US)",
volume = "16",
pages = "100--105",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer

AU - Pannek, J.

AU - Partin, Alan Wayne

PY - 1998

Y1 - 1998

N2 - Prostate-specific antigen (PSA) is the most important tumor marker for early detection, staging, and monitoring of men with prostatic cancer today. However, its sensitivity and specificity are not sufficient to use it as a single tool for screening for men with clinically localized prostate cancer. Recently, assays have become available that selectively detect several of the various molecular forms of PSA, especially the unbound or free PSA. Several studies have shown the clinical usefulness of percent free PSA (free PSA/total PSA) for the early detection of men with clinically localized prostate cancer. However, the use of percent free PSA for staging of prostate cancer remains controversial. Based on the case scenario presented, the value of total PSA and percent free PSA for the staging of men with clinically localized prostate cancer is reviewed.

AB - Prostate-specific antigen (PSA) is the most important tumor marker for early detection, staging, and monitoring of men with prostatic cancer today. However, its sensitivity and specificity are not sufficient to use it as a single tool for screening for men with clinically localized prostate cancer. Recently, assays have become available that selectively detect several of the various molecular forms of PSA, especially the unbound or free PSA. Several studies have shown the clinical usefulness of percent free PSA (free PSA/total PSA) for the early detection of men with clinically localized prostate cancer. However, the use of percent free PSA for staging of prostate cancer remains controversial. Based on the case scenario presented, the value of total PSA and percent free PSA for the staging of men with clinically localized prostate cancer is reviewed.

KW - Percent free PSA

KW - Prostate cancer

KW - PSA

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=0031857141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031857141&partnerID=8YFLogxK

M3 - Article

C2 - 9741413

AN - SCOPUS:0031857141

VL - 16

SP - 100

EP - 105

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 3

ER -